Treat-to-target by Email During Urate-lowering Therapy in Gout

Status Recruiting

Clinical Trial Summary

Gout is secondary to urate crystal deposition after chronic elevation of serum urate level (SUL). Long-term lowering SUL below 360 µmol/L allows dissolution of deposited crystals and disease cure. There is currently a paradoxical observation: while urate-lowering therapy (ULT) is available and efficient there is an increase of gout prevalence and severity. The apparent failure of ULT in gout management is due to several causes including unadjusted dosage, no SUL verification, irregular follow-up and low treatment compliance. In contrast, a nurse-led treat-to-target (T2T) strategy with regular adaptations of ULT until reaching SUL target allows gout cure in more than 90% of patients. We hypothesize that an electronic messaging-led T2T strategy will allow obtaining similar results. The aim of this study is to demonstrate that email-led T2T strategy during ULT is superior to usual care.

Clinical Trial Description

The study will include 204 gouty patients without ULT or with ineffective ULT. This is a multicenter and randomized study (e-mail follow-up vs usual follow-up groups). This study will include the following visits: - Selection/inclusion visit (V0): - If available biological data (leucocyte count, hemoglobin level, creatininemia and estimated glomerular filtration rate (eGFR), SUL) were assessed during the last month, , included patient will be randomized at the end of the consultation to follow either an email-led T2T strategy or usual ULT care. - In the absence of biological results, the patient will be reviewed within the month with blood analysis and then randomized. - Follow-up visits: consultations will be carried out according to the usual care of the referring physician. - Visit M12 end of research: clinical evaluation of gout, demographic characteristics, medication, type and dose of ULT, blood analysis (serum creatinine level, eGFR, SUL). The study ends after the M12 consultation. The total duration of participation in the study is 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04733079
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact	Korng EA, PH-PU
Phone	1 49 95 88 25
Email	hang-korng.ea@aphp.fr
Status	Recruiting
Phase	N/A
Start date	December 15, 2021
Completion date	October 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04060173` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671	Phase 1
Not yet recruiting	`NCT06187519` - UR+AIMS Gout Wearable Skin Uric Acid Monitor Study	N/A
Completed	`NCT03635957` - Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout	Phase 4
Completed	`NCT04966325` - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects	Early Phase 1
Completed	`NCT03015948` - A Single Dose Study of SHR4640 in Healthy Male Volunteers	Phase 1
Completed	`NCT02855437` - Novel Methods for Ascertainment of Gout Flares -A Pilot Study	N/A
Active, not recruiting	`NCT02702375` - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases	N/A
Completed	`NCT01407874` - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2
Completed	`NCT00995618` - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia	Phase 2
Completed	`NCT00985127` - Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout	Phase 2
Terminated	`NCT04987294` - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease	Phase 2
Completed	`NCT03291782` - D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers	Phase 1
Recruiting	`NCT03388515` - A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.	Phase 1
Completed	`NCT06189404` - Effect of Tigulixostat on the Pharmacokinetics of Theophylline	Phase 1
Enrolling by invitation	`NCT03336203` - The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)	Phase 4
Recruiting	`NCT05586958` - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients	Phase 3
Recruiting	`NCT04047394` - A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers	Phase 1
Not yet recruiting	`NCT05507723` - Tight Control of Gouty Arthritis Compared to Usual Care	N/A
Recruiting	`NCT06056570` - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia	Phase 1/Phase 2
Completed	`NCT02557126` - Study of URC102 to Assess the Safety and Efficacy in Gout Patients	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treat-to-target by Email During Urate-lowering Therapy in Gout — GOUTEmail

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms